How open is the therapeutic horizon for pancreatic cancer patients?
- 1 February 2022
- journal article
- editorial
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 21 (1) , 1-3
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisThe Lancet Oncology, 2016
- A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the PancreasAmerican Journal of Surgical Pathology, 2015
- Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and MetastasisCancer Cell, 2015
- Acid-base transport in pancreatic cancer: Molecular mechanisms and clinical potentialBiochemistry and Cell Biology, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor CellsGastroenterology, 2014
- A Surgical and Pathological Based Classification of Resective Treatment of Pancreatic CancerDigestive Surgery, 1999
- Immunological Escape Mechanisms in Pancreatic CarcinomaAnnals of the New York Academy of Sciences, 1999
- Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancerProceedings of the National Academy of Sciences, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997